Selective laser trabeculoplasty versus medical therapy as initial treatment of glaucoma: A prospective, randomized trial

Journal of Glaucoma

Volumn 21, Issue 7, 2012, Pages 460-468

  Katz, L Jay ^a   Steinmann, William C ^b   Kabir, Azad ^c   Molineaux, Jeanne ^a   Wizov, Sheryl S ^a   Marcellino, George ^d  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b University of Missouri   (United States)

^c Lumenis Inc   (United States)

^d UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

glaucoma; glaucoma medications; laser trabeculoplasty

Indexed keywords

BETAXOLOL; BIMATOPROST; BRIMONIDINE; BRINZOLAMIDE; DORZOLAMIDE; DORZOLAMIDE PLUS TIMOLOL; LATANOPROST; TIMOLOL; TRAVOPROST;

ADULT; ARTICLE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; FEMALE; HIGH RISK PATIENT; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN ANGLE GLAUCOMA; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SELECTIVE LASER TRABECULOPLASTY; TRABECULOPLASTY; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GLAUCOMA, OPEN-ANGLE; HUMANS; INTRAOCULAR PRESSURE; LASER THERAPY; LASERS, SOLID-STATE; MALE; MIDDLE AGED; OCULAR HYPERTENSION; PROSPECTIVE STUDIES; TONOMETRY, OCULAR; TRABECULECTOMY; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 84865991648     PISSN: 10570829     EISSN: 1536481X     Source Type: Journal    
DOI: 10.1097/IJG.0b013e318218287f     Document Type: Article

References (65)

1. Congdon N, O'Colmain B, Klaver CC, et al; Eye Diseases Prevalence Research Group. Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol. 2004;122:477-485.
2. Hattenhauer MG, Johnson DH, Ing HH, et al. The probability of blindness from open-angle glaucoma. Ophthalmology. 1998;105:2099-2104.
3. Kass MA, Gordon M, Morley RE Jr, et al. Compliance with topical timolol treatment. Am J Ophthalmol. 1987;15:188-193.
4. Schwartz GF, Reardon G, Mozaffari E. Persistency with latanoprost or timolol in primary open-angle glaucoma suspects. Am J Ophthalmol. 2004;137(1 suppl):S13-S16.
5. Rein DB, Zhang P, Wirth KE, et al. The economic burden of major adult visual disorders in the United States. Arch Ophthalmol. 2006;124:1754-1760.
6. The Glaucoma Laser Trial (GLT) 2. Results of Argon Laser Trabeculoplasty versus topical medicines. The Glaucoma Laser Trial Research Group. Ophthalmology. 1990;97:1403-1413.
7. The Glaucoma Laser Trial (GLT) and Glaucoma Laser Trial follow-up study: Glaucoma Laser Trial Research Group. Am J Ophthalmol. 1995;120:718-731.
8. Lichter PR, Musch DC, Gillespie BW, et al; CIGTS Study Group. Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment to medications or surgery. Ophthalmology. 2001;108:1943-1953.
9. Wise JB, Witter SL. Argon laser therapy for open angle glaucoma: a pilot study. Arch Ophthalmol. 1979;97:319-322.
10. Wise JB. Long-term control of adult open angle glaucoma by argon laser treatment. Ophthalmology. 1981;88:197-202.
11. Latina MA, Park C. Selective targeting of trabecular meshwork cells: in vitro studies of pulsed and CW laser interactions. Exp Eye Res. 1995;60:359-371.
12. Kramer TR, Noecker RJ. Comparison of the morphologic changes after selective laser trabeculoplasty and argon laser trabeculoplasty in human eye banks. Ophthalmology. 2001; 108:773-779.
13. Latina MA, Sibayan SA, Shin DH, et al. Q-switched 532nm Nd YAG laser trabeculoplasty (selective trabeculoplasty). A multicenter, pilot, clinical study. Ophthalmology. 1998;105: 2082-2090.
14. Kajiya S, Hayakawa K, Sawaguchi S. Clinical results of selective laser trabeculoplasty. Jpn J Ophthalmol. 2000;44:574-575.
15. Gracner T. Intraocular pressure response to selective laser trabeculoplasty in the treatment of primary open-angle glaucoma. Ophthalmologica. 2001;215:267-270.
16. Gracner T. Intraocular pressure response of capsular glaucoma and primary open-angle glaucoma to selective Nd:YAG laser trabeculoplasty: a prospective, comparative clinical trial. Eur J Ophthalmol. 2002;12:287-292.
17. Cvenkel B. One-year follow-up of selective laser trabeculoplasty in open-angle glaucoma. Ophthalmologica. 2004;218:20-25.
18. Lai JS, Chua JK, Tham CC, et al. Five-year follow up of selective laser trabeculoplasty in Chinese eyes. Clin Experiment Ophthalmol. 2004;32:368-372.
19. Francis BA, Ianchulev T, Schofield JK, et al. Selective laser trabeculoplasty as a replacement for medical therapy in openangle glaucoma. Am J Ophthalmol. 2005;140:524-525.
20. Juzych MS, Chopra V, Banitt MR, et al. Comparison of longterm outcomes of selective laser trabeculoplasty versus argon laser trabeculoplasty in open-angle glaucoma. Ophthalmology. 2004;111:1853-1859.
21. Damji KF, Shah KC, Rock WJ, et al. Selective laser trabeculoplasty v argon laser trabeculoplasty: a prospective randomised clinical trial. Br J Ophthalmol. 1999;83:718.
22. Damji KF, Bovell AM, Hodge WG, et al. Selective laser trabeculoplasty versus argon laser trabeculoplasty: results from a 1-year randomized clinical trial. Br J Ophthalmol. 2006;90: 1490-1494.
23. Martinez-de-la-Casa JM, Garcia-Feijoo J, Castillo A, et al. Selective versus argon laser trabeculoplasty: hypotensive efficacy, anterior chamber inflammation, and postoperative pain. Eye. 2004;18:498-502.
24. Melamed S, Ben-Simon GJ, Levkovitch-Verbin H. SLT as primary treatment for open-angle glaucoma: a prospective, nonrandomized pilot study. Arch Ophthalmol. 2003;121:957-960.
25. McIlraith L, Strasfeld M, Cloev G, et al. SLT as initial and adjunctive therapy for open angle glaucoma. J Glaucoma. 2006;15:124-130.
26. Van der Valk R, Webers CA, Schouten JS, et al. Intraocular pressure-lowering effects of all commonly used glaucoma drugs: a meta-analysis of randomized clinical trials. Am J Ophthalmol. 2005;112:1177-1185.
27. Nagar M, Ogunyomade A, O'brart DP, et al. A randomised, prospective study comparing selective laser trabeculoplasty with latanoprost for the control of intraocular pressure in ocular hypertension and open angle glaucoma. Br J Ophthalmol. 2005;89:1413-1417.
28. Migdal C, Hitchings R. Control of chronic simple glaucoma with primary medical, surgical, and laser treatment. Trans Ophthalmol Soc UK. 1986;105:653-656.
29. Janz NK, Wren PA, Litcher PR, et al. Quality of life in newly diagnosed glaucoma patients: the Collaborative Initial Glaucoma Treatment Study. Ophthalmology. 2001;108:887-897; discussion 898.
30. Patel SC, Spaeth GL. Compliance in patients prescribed eyedrops for glaucoma. Ophthalmic Surg. 1995;26:234-236.
31. Olthoff CM, Schouten JS, van de Borne BW, et al. Noncompliance with ocular hypotensive treatment in patients with glaucoma or ocular hypertension an evidence-based review. Ophthalmology. 2005;112:953-961.
32. Stewart WC, Konstas AG, Pfeiffer N. Patient and ophthalmologist attitudes concerning compliance and dosing in glaucoma treatment. J Ocul Pharmacol Ther. 2004;20:461-469.
33. Nordstrom BL, Friedman DS, Mozaffari E, et al. Persistence and adherence with topical glaucoma therapy. Am J Ophthalmol. 2005;140:598-606.
34. Robin AL, Covert D. Does adjunctive glaucoma therapy affect adherence to the initial primary therapy? Ophthalmology. 2005;112:863-868.
35. Osborne SA, Montgomery DM, Morris D, et al. Alphagan allergy may increase the propensity for multiple eye-drop allergy. Eye. 2005;19:129-137.
36. Nelson WL, Fraunfelder FT, Sills JM, et al. Adverse respiratory and cardiovascular events attributed to timolol ophthalmic solution, 1978-1985. Am J Ophthalmol. 1986;102: 606-611.
37. Brandt JD, Wittpenn JR, Katz LJ, et al. Conjunctival impression cytology in patients with glaucoma using longterm topical medications. Am J Ophthalmol. 1991;112:297-301.
38. Noecker RJ, Herrygers LA, Anwaruddin R. Corneal and conjunctival changes caused by commonly used glaucoma medications. Cornea. 2004;23:490-496.
39. Broadway DC, Grierson I, O'Brien C, et al. Adverse effects of topical antiglaucoma medication. I. The conjunctival cell profile. Arch Ophthalmol. 1994;112:1437-1445.
40. Broadway DC, Grierson I, O'Brien C, et al. Adverse effects of topical antiglaucoma medication. II. The outcome of filtration surgery. Arch Ophthalmol. 1994;112:1446-1454.
41. Bergea B, Bodin L, Svedbergh B. Impact of IOP regulation on visual fields in open angle glaucoma. Ophthalmology. 1999;106: 997-1005.
42. Asrani S, Zeimer R, Wilensky J, et al. Large diurnal fluctuations in intraocular pressure are an independent risk factor in patients with glaucoma. J Glaucoma. 2000;9:134-142.
43. Nouri-Mahdavi K, Hoffman D, Coleman AL, et al. Predictive factors for glaucomatous visual field progression in the Advanced Glaucoma Intervention Study. Ophthalmology. 2004;111:1627-1635.
44. Liu JH, Kripke DF, Weinreb RN. Comparison of the nocturnal effects of once-daily timolol and latanoprost on intraocular pressure. Am J Ophthalmol. 2004;138:389-395.
45. Walters TR. 24-Hour IOP control with once-daily bimatoprost, timolol gel-forming solution, or latanoprost: a 1-month, randomized, comparative clinical trial Surv Ophthalmol. 2004;49(suppl 1):S26-S35.
46. Sherwood MB, Craven ER, Chou C, et al. Twice-daily 0.2% brimonidine-0.5% timolol fixed-combination therapy versus monotherapy with timolol or brimonidine in patients with glaucoma or ocular hypertension: a 12-month randomized trial. Arch Ophthalmol. 2006;124:1230-1238.
47. Greenidge KC, Spaeth GL, Fiol-Silva Z. Effect of argon laser trabeculoplasty on the glaucomatous diurnal curve. Ophthalmology. 1983;90:800-804.
48. Elsas T, Junk H, Johnsen H. Diurnal intraocular pressure after successful primary laser trabeculoplasty. Am J Ophthalmol. 1991;112:67-69.
49. Lee R, Hutnik CM. Projected cost comparison of selective laser trabeculoplasty versus glaucoma medication in the Ontario Health Insurance Plan. Can J Ophthalmol. 2006;41: 449-456.
50. Cantor LB, Katz LJ, Cheng JW, et al. Economic evaluation of medication, laser trabeculoplasty and filtering surgeries in treating patients with glaucoma in the US. Curr Med Res Opin. 2008;24:2905-2918.
51. AGIS Investigators. The advanced glaucoma intervention study (AGIS): 4. Comparison of treatment outcomes within race-7 year results. Ophthalmology. 1998;105:1146-1164.
52. Shingleton BJ, Richter CU, Dharma SK, et al. Long-term efficacy of argon laser trabeculoplasty. A 10-year follow-up study. Ophthalmology. 1993;100:1324-1329.
53. Lotti R, Traverso CE, Murialdo U, et al. Argon laser trabeculoplasty: long-term results. Ophthalmic Surg. 1995; 26:127-129.
54. Spaeth GL, Baez KA. Argon laser trabeculoplasty controls one third of cases of progressive, uncontrolled, open angle glaucoma for 5 years. Arch Ophthalmol. 1992;110:491-494.
55. Richter CU, Shingleton BJ, Bellows AR, et al. Retreatment with argon laser trabeculoplasty. Ophthalmology. 1987;94: 1085-1089.
56. Feldman RM, Katz LJ, Spaeth GL, et al. Long-term efficacy of repeat argon laser trabeculoplasty. Ophthalmology. 1991;98: 1061-1065.
57. Grayson DK, Camras CB, Podos SM, et al. Long-term reduction of intraocular pressure after repeat argon laser trabeculoplasty. Am J Ophthalmol. 1988;106:312-321.
58. Latina MA, Gulati V. Selective laser trabeculoplasty: stimulating the meshwork to mend its ways. Int Ophthalmol Clin. 2004;44:93-103.
59. Bylsma SS, Samples JR, Acott TS, et al. Trabecular cell division after argon laser trabeculoplasty. Arch Ophthalmol. 1988;106:544-547.
60. Acott TS, Samples JR, Bradley JM, et al. Trabecular repopulation by anterior trabecular meshwork cells after laser trabeculoplasty. Am J Ophthalmol. 1989;107:1-6.
61. Dueker DK, Norberg M, Johnson DH, et al. Stimulation of cell division by argon and Nd:YAG laser trabeculoplasty in cynomolgus monkeys. Invest Ophthalmol Vis Sci. 1990;31:115-124.
62. Alvarado JA, Alvarado RG, Yeh RF, et al. A new insight into the cellular regulation of aqueous outflow: how trabecular meshwork endothelial cells drive a mechanism that regulates the permeability of Schlemm's canal endothelial cells. Br J Ophthalmol. 2005;89:1500-1505.
63. Chen TC, Ang RT, Grosskreutz CL, et al. Brimonidine 0.2% versus apraclonidine 0.5% for prevention of intraocular pressure elevations after anterior segment laser surgery. Ophthalmology. 2001;108:1033-1038.
64. Barnes SD, Campagna JA, Dirks MS, et al. Control of intraocular pressure elevations after argon laser trabeculoplasty: comparison of brimonidine 0.2% to apraclonidine 1.0%. Ophthalmology. 1999;106:2033-2037.
65. Harasymowycz PJ, Papamatheakis DG, Latina M, et al. Selective laser trabeculoplasty (SLT) complicated by intraocular pressure elevation in eyes with heavily pigmented trabecular meshworks. Am J Ophthalmol. 2005;139:1110-1113.